Family offices in Germany and the DACH region still approach life sciences with caution. I see that as one of the biggest missed opportunities of our generation.
Excited to make the case at bio:cap in Berlin on June 10, alongside Andreas Schmidt, Leo Wang and Angela De Giacomo, on "Family Offices and the Next Wave of Life Sciences Investment."
We are watching several worlds converge at once: #biotech, precision medicine and diagnostics, but also prevention, #longevity, and increasingly the consumer side of enhancement and #lifestyle. AI is compressing timelines and cost across all of it. For patient, cross-generational capital, this is the ultimate impact investment, combining above-average returns with measurable, real-world benefit to people's lives.
#Europe does not lack talent or science. What it lacks is risk appetite and capital deployed with conviction. If we want stronger innovation ecosystems here, family offices have a decisive role to play.
Looking forward to the conversation in Berlin.
During bio:cap , I am hosting a small dinner for Family Offices and High Net Worths interestd in biotech deals, DM me if you want to join.
@RobinLauber_@lmkifiwin@Megan__Romano was our absolute favourite - this gave us goosebumps and proves the whole thesis. And, YES you've set the the blueprint, Megan!
https://t.co/c53lb3WUj5
Interesting perspective from our Co-Founder @RobinLauber_ following the @enhanced_games.
The intersection of longevity, human enhancement and technology remains an area worth paying attention to as new markets and categories continue to emerge.
A few moments from the weekend, with @C_Angermayer , @max_enhanced and the @enhanced_games team.
Interesting few days and great conversations across the gala and science sessions.
Many of the discussions ultimately came back to longevity and human optimisation - and how clinical advances are beginning to shape mainstream healthcare trends.
For decades, healthcare has largely focused on treatment. Now, the conversation is expanding towards prevention, performance and extending healthy lifespan.
On the event itself, for me the most imortant findings were that many athletes like @Megan__Romano & @swimiller , who were out of competition for 5-10 years were able to set PBs, and some made more money than in their entire career. Life changing for them and their families, and on top most of the athletes said they feel better than ever before (sleep, mentally, resting heart rate...).
Sharing this from @RobinLauber_ ahead of Sunday.
Infinitas backed @enhanced_games early — the convergence of healthcare, prevention and enhancement is one of the defining themes of the decade, and Enhanced is the first platform built for it.
Sunday is just the beginning. $ENHA
THIS IS HAPPENING!
Heading to Vegas tonight for a dinner with friends, investors who shared @InfinitasCap 's mission investing into @enhanced_games , ahead of Sunday's inaugural Games.
Healthcare, prevention, enhancement — GLP-1s, HRT, psychedelics, peptides — it's all becoming one category. Sunday is the first time the world gets to see it on a stage.
Let's go.
Congrats to @C_Angermayer and the entire Enhanced team!
https://t.co/X8QTgzOw14
The Infinitas team is off to Las Vegas for @enhanced_games.
We are hosting our investor dinner on Friday and will be spending time with founders, scientists and investors over the weekend discussing longevity, optimisation and where these shifts may lead.
Our portco Enhanced just closed its first week trading on the NYSE ($ENHA) after listing May 8. 🔔
At Infinitas Capital, we back biotech breakthroughs with real-world impact.
Congrats to Max, Christian, and team. See you May 24 in Las Vegas. 🧬🚀
A historic day at the @NYSE. 🏛️
We couldn’t be more excited to begin this journey as a public company. Let’s make history.
See you on May 24 in Las Vegas. $ENHA
Four patients. Up to $7B.
That's what Lilly paid for Kelonia this week. Their second in vivo CAR-T deal of the year, after Orna in February.
CAR-T transformed oncology. The delivery model is broken. In vivo fixes it — and unlocks autoimmune.
We're leading a round in a platform that combines what Orna and Kelonia are each doing separately. We believe it can become bigger than either. 😉
More soon.
https://t.co/qrDgmRJYiK
Delighted to see @Bloomberg feature the launch of Aureon Capital.
A listed investment vehicle opening access to private growth companies - combining private market upside with public market liquidity.
Now progressing to a Nasdaq Stockholm listing.
https://t.co/CGdEFXvXDC
Our Co-Founder @RobinLauber_ spoke to @vc_magazin to discuss how we preserve wealth, while investing in breakthroughs shaping the future.
In this cover interview, accessed here, Robin highlights novel life sciences that deliver measurable social impact: https://t.co/aIxyv2e30Z
Sweden has one of Europe’s strongest equity markets🚀.
We are launching a Swedish investment platform aiming to list on Nasdaq Stockholm in 2026.
Platform will acquire up to 25% of HausVorteil AG.
Alexander Landorph joins to lead Nordic expansion.
More: https://t.co/joVnPA8PPa
Great conversation between our founder Robin Lauber and Marvin Hauser.
The episode highlights how Infinitas Capital approaches capital allocation across multiple risk layers — combining stable real estate cashflows with selective exposure to higher-growth opportunities.
Really enjoyed this conversation with Marvin Hauser — thanks again for having me on.
We spoke about how we at infinitas capital think about capital allocation across very different risk layers — and why real estate is still the foundation that allows us to take intelligent risk elsewhere.
This time we went deeper into:
🏢 Information asymmetry in Swiss real estate — why local edge still matters more than spreadsheets
🏗️ Structuring large-scale developments with private capital
🇸🇪 Why Sweden can be a more attractive IPO market than Germany for growth companies
🧬 The foundation of success in biotech investing — management quality, incentives, execution
⏳ And yes… the modern “fountain of youth” — why longevity isn’t science fiction anymore but an investable reality
Appreciate the thoughtful questions and the opportunity to go beyond surface-level investing talk.
If you’re interested in how we combine stable cashflow with asymmetric upside, it’s worth a listen.
https://t.co/UHbeHu8Gvs
Excited to see Cambrian Bio awarded up to $30.8M from ARPA-H’s PROSPR program, validating its TORnado platform to slow age-related metabolic decline. A strong signal for longevity investing. Congrats to James Peyer and team!
https://t.co/fU0Bvjn0dd